Meeting of the Psychopharmacologic Drugs Advisory Committee Meeting

Meeting of the Psychopharmacologic Drugs Advisory Committee Meeting Committee Meeting March 21, 2013 8:00 a.m. to 5:00 p.m. Agenda : On March 21, 2013, the committee will discuss new drug application (NDA) 204442, PROBUPHINE (buprenorphine hydrochloride and ethylene vinyl acetate) subdermal implant, submitted by Titan Pharmaceuticals, Inc., and its safety and efficacy for the proposed indication of maintenance treatment of opioid dependence.